Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men

Stuver, Sherri O.; Kuper, Hannah; Τζώνου, Αναστασία; Λάγιου, Παγώνα; Spanos, Evangelos; Hsieh, Chung‐Cheng; Mantzoros, Christos S.; Trichopoulos, Dimitrios

doi:10.1002/1097-0215(20000701)87:1<118::aid-ijc17>3.0.co;2-w

Cited by 64 publications

(55 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of our prospective study are in opposition to what was found in other malignancies, 9 -12 although they are in agreement with what was described in previous retrospective reports demonstrating low IGF-I levels in patients with HCC. 14,16 Despite this concordance of results, it remains difficult to find any physiopathologic significance to this clinical observation. The lack of data about the IGFBPs prevented clarification about whether low serum IGF-I levels in our patients with HCC may have reflected a decrease in the production of transport proteins as a consequence of the destruction of liver parenchyma by the tumor.…”

Section: Discussionmentioning

confidence: 99%

“…The possibility of a paracrine feed-back loop that regulates serum IGF-I levels in the presence of HCC has been suggested previously. 16 According to this hypothesis, the low circulating IGF-I levels may derive from an inhibitory effect by some tumor cytokines, like tumor growth factor ␤ and platelet-derived growth factor. 28 Indeed, these cytokines are over-expressed in patients with HCC in relation to the degree of fibrogenic activity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis

Mazziotti

Sorvillo

Morisco³

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUNDAlthough experimental studies have demonstrated an important role of insulin‐like growth factor I (IGF‐I) in hepatocarcinogenesis, the clinical data about IGF‐I in patients with hepatocellular carcinoma (HCC) are scarce and controversial. To the authors' knowledge, this is the first prospective study investigating the longitudinal correlation between modifications in serum IGF‐I levels and the development of HCC in a cohort of patients with hepatitis C virus (HCV)‐related cirrhosis.METHODSOne hundred fourteen consecutive patients with HCV‐related Child Grade A cirrhosis were followed prospectively at the Second University of Naples for 56.4 ± 12.0 months with ultrasound examinations of the liver and serum α‐fetoprotein determination every 6 months. At each clinical evaluation, the severity of disease was graded according to the established Child–Pugh scoring system. Serum IGF‐I levels were measured prospectively at the study entry and at least every 12 months throughout follow‐up.RESULTSTwenty patients (19.2%) developed HCC during follow‐up. Eleven of these patients had persistent Child Grade A cirrhosis for the whole study, whereas the other 9 patients developed HCC after their cirrhosis progressed from Child Grade A to Grade B. In patients who remained free of HCC for the whole study, serum IGF‐I concentrations did not modify significantly during follow‐up. Conversely, in patients who developed HCC, IGF‐I levels decreased significantly during follow‐up (from 72.6 ± 29.9 μg/L to 33.8 ± 14.5 μg/L; P = 0.001). In these patients, the significant decrease occurred both in patients with persistent Child Grade A cirrhosis and in patients with cirrhosis that progressed from Child Grade A to Grade B. The reduction in IGF‐I level preceded the diagnosis of HCC by 9.3 ± 3.1 months.CONCLUSIONSThis prospective study demonstrates that, in patients with HCV‐related cirrhosis, 1) the development of HCC is accompanied by a significant reduction of serum IGF‐I levels independent of the grade of impairment of liver function; and 2) modification of the IGF‐I level precedes the morphologic appearance of HCC, permitting a precocious diagnosis of the tumor. Cancer 2002;95:2539–45. © 2002 American Cancer Society.DOI 10.1002/cncr.11002

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis

Mazziotti

Sorvillo

Morisco³

et al. 2002

Cancer

View full text Add to dashboard Cite

show abstract

“…30 However, in a study of 53 patients, circulating IGF-I levels were significantly lower in HCC compared with normal. 29 In this report, we observed barely detectable levels of IGF-I mRNA in HCC specimens. Although we saw no significant differences in circulating levels of IGF-I between HCC and sham-operated animals, we observed significantly elevated levels of IGF-I mRNA in normal liver from tumor-burdened animals.…”

Section: Discussionmentioning

confidence: 99%

Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma

et al. 2002

View full text Add to dashboard Cite

“…Many studies have suggested that high circulating IGF-I levels are associated with increased risk of prostate, premenopausal breast, and colon cancer (26); however, an inverse association has also been reported for gastric (27), endometrial (28,29), liver (30), and lung cancer (31). In this study we found an inverse association between cervical cancer risk and IGF-I circulating levels.…”

Section: Discussionmentioning

confidence: 99%

Niveles séricos de los factores de crecimiento similares a la insulina I y II y su proteína 3 de enlace en mujeres con lesiones escamosas intraepiteliales y cáncer de cuello uterino

Serrano¹,

Romero²,

Cendales³

et al. 2006

biomedica

View full text Add to dashboard Cite

Introduction. Pap smear has limitations as a screening test for cervical cancer. A marker that allows the identification of women who are at risk of developing cervical cancer would be useful for its prevention. A growing number of studies have demonstrated an association between insulin-like growth factors (IGF) serum levels and increased risk for various cancers. Objective. To assess whether circulating IGF-I, IGF-II, or IGF binding protein 3 (IGFBP-3) were associated with cervical cancer and low-grade and high-grade squamous intraepithelial lesions (LSIL and HSIL). Materials and methods. Serum levels of IGF-I, IGF-II and IGFBP-3 were measured by ELISA. Three groups of cases were analyzed: LSIL (n = 37), HSIL (n = 57), and cervical cancer (n = 41). For each case, two controls, matched by age, were included. Control subjects were women with normal, HPV-DNA-negative Pap smear. Results.Significantly lower values of IGF-I (83.9 ng/ml versus 126.6 ng/ml, p < 0.001) and IGF-I:IGFBP-3 molar ratio (0.094 versus 0.137, p < 0.001) were observed among cancer cases, as compared to their control group. Women in the highest quartile of IGF-I and IGF-I:IGFBP-3 molar ratio were at an 80% (OR = 0.2, 95% CI [0.06-0.61]) and a 77% (OR = 0.23, 95% CI [0.07-0.73]) lower risk of cervical cancer, respectively, compared with women in the corresponding reference category. Conclusions. These data suggest that low values of IGF-I and IGF-I:IGFBP-3 molar ratio may be associated with cervical cancer.

show abstract

Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men

Cited by 64 publications

References 31 publications

Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis

Serum insulin‐like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis

Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma

Niveles séricos de los factores de crecimiento similares a la insulina I y II y su proteína 3 de enlace en mujeres con lesiones escamosas intraepiteliales y cáncer de cuello uterino

Contact Info

Product

Resources

About